ClinicalTrials.gg

Program

quabodepistat

Also written as “Quabodepistat”, “OPC-167832 10 mg” and “OPC-167832 30 mg”.

Its studies are mostly in Tuberculosis, Pulmonary · Tuberculosis, Multidrug-Resistant · Tuberculosis, led by Otsuka.

Furthest: phase 3, since Aug 12, 20255 company-led studies, 1 open or runningNext primary completion: Sep 29, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka51 open or runningphase 3since Aug 12, 2025Sep 18, 2018Sep 29, 2028phase 3 · NCT07209761

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 18, 2018First study: phase 2 study in Tuberculosis, PulmonaryFirst studyNCT03678688 · 122 enrolled · South Africa
  2. Aug 20, 2021Phase 2 study in Tuberculosis, PulmonaryNCT05221502 · 122 enrolled · South Africa
  3. Aug 12, 2025Phase 3 study in Tuberculosis, Multidrug-ResistantNCT07209761 · 532 planned · China, Georgia, India and more
  4. Dec 18, 2025Phase 1 study in Healthy VolunteersNCT07314320 · 8 enrolled · United States
  5. Apr 14, 2026Phase 1 study in TuberculosisNCT07542847 · 24 enrolled · United States
  6. Oct 26, 2026Primary completion moved from 2027-05-28 to 2028-09-29Date moved laterphase 3 · +16 months · NCT07209761

Ahead

  1. Sep 29, 2028Primary completion: phase 3 study in Tuberculosis, Multidrug-ResistantNCT07209761

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07542847Tuberculosis · United States1CompletedNov 18, 202224
NCT07314320Healthy Volunteers · United States1CompletedDec 27, 20238
NCT07209761Tuberculosis, Multidrug-Resistant · China, Georgia, India and more3RecruitingSep 29, 2028532
NCT05221502Tuberculosis, Pulmonary · South Africa2CompletedApr 8, 2024122
NCT03678688Tuberculosis, Pulmonary · South Africa2CompletedFeb 14, 2022122

How it is read

Names in the registry

  • “Quabodepistat”, 1 entry
  • “OPC-167832 10 mg”, 1 entry
  • “OPC-167832 30 mg”, 1 entry
  • “OPC-167832 90 mg”, 1 entry
  • “OPC-167832”, 1 entry

Codes read as this program: OPC167832.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.